View clinical trials related to Aggressive Fibromatosis.
Filter by:This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.
The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.